Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemoglobin (oxidized) refers to hemoglobin in which the iron atom within its heme group is in a higher oxidation state, typically ferric (Fe3+) or, less commonly, ferryl (Fe4+). In its oxidized forms, hemoglobin loses its ability to bind and transport oxygen efficiently. Accumulation of oxidized forms like methemoglobin not only impairs tissue oxygen delivery but also promotes oxidative damage through ROS production and release of toxic free hemin. These processes are relevant both physiologically for redox balance control and pathologically during diseases involving increased oxidative stress or massive cell lysis.
N/A - not a drug target in the traditional sense. Interventions aim to reduce its formation or counteract its effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin (oxidized) (None).